scholarly journals Prognostic Signification of Admission Hyperglycemia among Acute Stroke Patients in Intensive Care Units in Kinshasa, the Democratic Republic of the Congo

2019 ◽  
Vol 09 (09) ◽  
pp. 665-680
Author(s):  
Josée K. Tshituta ◽  
François B. Lepira ◽  
François P. Kajingulu ◽  
Jean Robert R. Makulo ◽  
Ernest K. Sumaili ◽  
...  
2007 ◽  
Vol 254 (10) ◽  
Author(s):  
Uwe Walter ◽  
Rupert Knoblich ◽  
Volker Steinhagen ◽  
Martina Donat ◽  
Reiner Benecke ◽  
...  

2008 ◽  
Vol 270 (1-2) ◽  
pp. 60-66 ◽  
Author(s):  
Jiann-Shing Jeng ◽  
Sheng-Jean Huang ◽  
Sung-Chun Tang ◽  
Ping-Keung Yip

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sung-Chun Tang ◽  
Shyang-Rong Shih ◽  
Shin-Yi Lin ◽  
Chih-Hao Chen ◽  
Shin-Joe Yeh ◽  
...  

AbstractThis pilot, randomized, open-label controlled study compared the basal–bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. The study recruited acute stroke patients requiring intensive care within 72 h (h) of onset and had blood glucose > 200 mg/dL. 50 patients received IG (n = 26) or NPH (n = 24) with added short-acting prandial regular insulin over a 72-h period. The primary end point was the percentage of glucose within 80–180 mg/dL assessed through continuous glucose monitoring. The baseline characteristics were comparable, except the IG had higher glucose pre-randomization than the NPH (290.69 ± 82.31 vs. 246.04 ± 41.76 mg/dL, P = 0.021). The percentage of time with glucose between 80 and 180 mg/dL was 45.88 ± 27.04% in the IG and 53.56 ± 22.89% in the NPH (P = 0.341) and the percentage of glucose reduction was 31.47 ± 17.52% in the IG and 27.28 ± 14.56% in the NPH (P = 0.374). The percentage of time with glucose < 60 mg/dL was 0.14 ± 0.49% in the IG and 0.47 ± 1.74% in the NPH. Poststroke outcomes were not significantly different. In conclusion, IG is safe and equally effective as an NPH-based basal-bolus regimen for acute stroke patients with hyperglycemia receiving intensive care.Trial registration ClinicalTrials.gov, NCT02607943. Registered 18/11/2015, https://clinicaltrials.gov/ct2/show/NCT02607943.


Medicine ◽  
2021 ◽  
Vol 100 (32) ◽  
pp. e26913
Author(s):  
Han Eum Choi ◽  
Jae Hyun Lee ◽  
Young-Joo Sim ◽  
Ho Joong Jeong ◽  
Ghi Chan Kim

2020 ◽  
Author(s):  
Sung-Chun Tang ◽  
Shyang-Rong Shih ◽  
Shin-Yi Lin ◽  
Chih-Hao Chen ◽  
Shin-Joe Yeh ◽  
...  

Abstract Background: This pilot study compared the basal–bolus regimens of long-acting insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in efficacy and safety in acute stroke patients with hyperglycemia receiving intensive care (NCT02607943).Methods: This was a randomized, open-label, clinical trial. Stroke patients who were admitted to the intensive care unit within 72 h of onset and met the inclusion criteria were enrolled. They received either IG or NPH with added short-acting prandial regular insulin over a 72-h period. The primary endpoints were the percentage of glucose within the range of 80 to 180 mg/dL and the percentage of glucose reduction compared with pre-randomization glucose levels, assessed through continuous glucose monitoring (CGM).Results: A total of 50 patients were included, 26 and 24 were randomly assigned to the IG and NPH, respectively. The participant baseline characteristics were comparable between groups, except the IG had a significantly higher glucose level pre-randomization than the NPH (290.69 ± 82.31 versus 246.04 ± 41.76 mg/dL, P = .021). CGM data showed that the percentage of time with glucose levels between 80 and 180 mg/dL was 45.88 ± 27.04% in the IG and 53.56 ± 22.89% in the NPH (P = .341) and the percentage of glucose reduction was 31.47 ± 17.52% in the IG and 27.28 ± 14.56% in the NPH (P = .374). The percentage of time with hypoglycemia (< 60 mg/dl) was 0.14 ± 0.49% in the IG and 0.47 ± 1.74% in the NPH (P = .361). Parameters representative of glucose variabilities, and poststroke outcomes were not significantly different between the groups.Conclusions: Our study results suggest that early initiation of an IG-based basal–bolus regimen is safe and equally effective as an NPH-based basal-bolus regimen for patients with acute stroke and hyperglycemia requiring intensive care.Trial registration: ClinicalTrials.gov, NCT02607943. Registered 18 Nov 2015, https://clinicaltrials.gov/ct2/show/NCT02607943


Sign in / Sign up

Export Citation Format

Share Document